Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.6Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 1.25%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Neutral
TriSalus Life Sciences demonstrated strong revenue growth and expansion of its PEDD technology despite a challenging economic environment. The issuance of a new HCPCS code by CMS and strategic cost reductions were positive developments. However, the delay in filing the 10-K and ongoing operating losses highlight some operational challenges. The overall sentiment is cautiously optimistic with a focus on future growth.Company Guidance
During the TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided guidance for 2025, projecting over 50% revenue growth, positive full-year EBITDA, and cash flow in the second half of the year. Key metrics from 2024 included $29.4 million in net sales, representing a 59.4% increase over 2023, and a 44% growth in the fourth quarter alone. The company expanded its market presence by opening 103 new accounts and increased the number of unique ordering accounts by 43%, with the average units sold per ordering account rising by 10%. TriSalus also reported robust gross margins of 85% in Q4 2024 and 86% for the full year. The company is advancing its pipeline, notably with the TriNav technology, and expects to continue its growth trajectory with strategic initiatives and expanded clinical applications.Strong Revenue Growth
TriSalus reported $29.4 million in net sales for 2024, reflecting a 59.4% growth over 2023. The company also achieved a 44% revenue increase in Q4 2024 compared to Q4 2023.
Expansion of PEDD Technology
The company successfully expanded its pressure-enabled drug delivery (PEDD) technology into new clinical applications, achieving 43% growth in unique ordering accounts and a 10% increase in average units sold per account.
New HCPCS Reimbursement Code
CMS issued a new HCPCS code C8004 for simulation or mapping procedures using TriNav, effective April 1, 2025, ensuring financial support for clinicians using TriNav in Medicare treatment planning.
Gross Margin Stability
TriSalus maintained a robust gross margin profile of 85% in Q4 2024 and 86% for the full year, indicating efficient cost management.
Significant Reduction in R&D Expenses
R&D expenses decreased by 62% in Q4 2024 compared to Q4 2023 and by 41% for the full year, reflecting strategic cost management.
---
TLSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TLSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $5.58 | $5.50 | -1.43% |
| Nov 14, 2024 | $4.50 | $4.01 | -10.89% |
| Aug 15, 2024 | $5.85 | $5.89 | +0.68% |
| May 15, 2024 | $10.15 | $9.39 | -7.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TriSalus Life Sciences (TLSI) report earnings?
TriSalus Life Sciences (TLSI) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is TriSalus Life Sciences (TLSI) earnings time?
TriSalus Life Sciences (TLSI) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLSI EPS forecast?
TLSI EPS forecast for the fiscal quarter 2025 (Q1) is -0.22.
---